Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,514.37 65.12 0.40%
S&P 500 1,879.55 7.66 0.41%
NASDAQ 4,161.46 39.91 0.97%
Ticker Volume Price Price Delta
STOXX 50 3,191.40 -8.29 -0.26%
FTSE 100 6,688.25 6.49 0.10%
DAX 9,583.76 -16.33 -0.17%
Ticker Volume Price Price Delta
NIKKEI 14,546.27 157.50 1.09%
TOPIX 1,173.81 11.31 0.97%
HANG SENG 22,526.33 -204.35 -0.90%

SIGA to Host Third Quarter Business Update Call on November 5, 2012



SIGA to Host Third Quarter Business Update Call on November 5, 2012

NEW YORK, Oct. 29, 2012 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc.
(Nasdaq:SIGA), a company specializing in the development of pharmaceutical
agents to fight lethal disease causing pathogens, announced today that
management will host a conference call and simultaneous webcast to provide a
quarterly business update at 4:30 P.M. ET on Monday, November 5, 2012.

Participants should call (877) 303-9231 (United States/Canada) or (760)
666-3567 (International) and request the SIGA call or provide confirmation
code 59766553. A live broadcast of the call will be available on the Company's
website at www.SIGA.com under the 'Events & Presentations' tab in the Investor
Relations section.

A replay of the call will be available approximately two hours after the call
and will be accessible until 11:59 P.M. ET on November 19, 2012. To listen to
the replay, dial (855) 859-2056 (Domestic) or (404) 537-3406 (International)
and enter the code 59766553. The webcast of the event will also be archived on
the Company's website for two weeks under the 'Events & Presentations' tab in
the Investor Relations section.

About SIGA Technologies, Inc.

Communities in the United States and around the world face a serious but unmet
need for drugs to protect against potentially catastrophic emerging viral
pathogens and biological weapons of mass destruction. We are a pharmaceutical
company specializing in the development and commercialization of
pharmaceutical solutions for some of the most lethal disease-causing pathogens
in the world - smallpox, Ebola, dengue, Lassa fever and other dangerous
viruses. Our business is to discover, develop, manufacture and successfully
commercialize drugs to prevent and treat these high-priority threats. Our
mission is to disarm dreaded viral diseases and create robust, modern
biodefense countermeasures. For more information about SIGA, please visit
SIGA's web site at www.siga.com.

The SIGA Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4504

Forward-looking Statements

This press release contains certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995, as amended,
including statements relating to the outcome of the litigation with
PharmAthene, Inc. Forward-looking statements are based on management's
estimates, assumptions and projections, and are subject to uncertainties, many
of which are beyond our control. Actual results may differ materially from
those anticipated in any forward-looking statement. Factors that may cause
such differences include (i) the risk that potential products that appear
promising to us or our collaborators cannot be shown to be efficacious or safe
in subsequent pre-clinical or clinical trials, (ii) the risk that we or our
collaborators will not obtain appropriate or necessary governmental approvals
to market these or other potential products, (iii) the risk that we may not be
able to obtain anticipated funding for our development projects or other
needed funding, (iv) the risk that we may not be able to secure funding from
anticipated or current government contracts and grants, (v) the risk that we
may not be able to secure or enforce sufficient legal rights in our products,
including patent protection, (vi) the risk that any challenge to our patent
and other property rights, if adversely determined, could affect our business
and, even if determined favorably, could be costly, (vii) the risk that
regulatory requirements applicable to our products may result in the need for
further or additional testing or documentation that will delay or prevent
seeking or obtaining needed approvals to market these products, (viii) the
risk that one or more protests could be filed and upheld in whole or in part
or other governmental action taken, in either case leading to a delay of
performance under our contract with the Biomedical Advanced Research and
Development Authority (BARDA) or other governmental contracts, (ix) the risk
that our BARDA contract is modified or cancelled at the request or requirement
of the U.S. government, (x) the risk that the adverse portions of the
post-trial decision by the Delaware Chancery Court in the litigation brought
by PharmAthene, Inc. will be upheld in further proceedings, including any
appeal, or that the favorable portions will be modified, (xi) the risk that
the volatile and competitive nature of the biotechnology industry may hamper
our efforts to develop or market our products, (xii) the risk that changes in
domestic and foreign economic and market conditions may adversely affect our
ability to advance our research or products, and (xiii) the effect of any
change to federal, state or foreign regulation, including drug regulation and
international trade regulation, on our business. More detailed information
about our company and risk factors that may affect the realization of
forward-looking statements, including the forward-looking statements set forth
here, is set forth in our filings with the Securities and Exchange Commission
(the SEC), including our Annual Report on Form 10-K for the fiscal year ended
December 31, 2011, and in other documents that we have filed with the SEC. We
urge investors and security holders to read those documents free of charge at
the SEC's Web site at http://www.sec.gov. Interested parties may also obtain
those documents free of charge directly from us. Forward-looking statements
speak only as of the date they are made, and except for our ongoing
obligations under the federal securities laws, we undertake no obligation to
update publicly any forward-looking statement whether as a result of new
information, future events or otherwise.

CONTACT: KCSA Strategic Communications
         Todd Fromer / Rob Fink
         212-896-1215 / 1206
         Tfromer@kcsa.com / rfink@kcsa.com

company logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement